David Resnick

David Resnick is a partner and the co-team leader of the Biotechnology/Chemistry team at Nixon Peabody. David assists clients in obtaining and defending intellectual property protection for cutting edge technologies in the life sciences, including stem cells, regenerative medicine and RNAi. David has developed a particular focus on the areas on pharmacogenomics, proteomics, and disease biomarkers and their application in the evolving field of personalized medicine.

David also assists clients by evaluating their intellectual property portfolios, as well as the intellectual property held by competitors or potential acquisitions or partners. In connection with these activities, he has been involved with strategic patent prosecution, due diligence and freedom-to-operate analyses.

David’s clients include many Boston area universities, research hospitals, and life science startups, as well as large pharmaceutical companies.

Recent posts and comments

• Baseball, Steroids, and Patent Reform

  If you have been following the news in the last month or so, you’ve probably watched in amazement as Congress tackles one of our country’s most pressing issues. I’m not talking... Read more »

• Commenting on: Folkman Leaves Behind an Inspiring Legacy of Science, Learning, and Startups

  David said: Thank you for your article. Dr. Folkman was an amazing man. Not only was he a brilliant scientist,... Read more »

• This is Personal: A Legislative Attack on Personalized Medicine

  It has long been known that different individuals react to the same drug differently. Matching the right therapy with the right individual, commonly know as “personalized medicine,” could improve treatment, reduce... Read more »